Funded Biotechnology Startups in Sunnyvale
The 10 most recent funding events among Sunnyvale biotechnology startups span September 2022 through October 2025, with activity concentrating in the 2024–…
The 10 most recent funding events among Sunnyvale biotechnology startups span September 2022 through October 2025, with activity concentrating in the 2024–2025 window. Rubedo Life Sciences raised the largest disclosed round in this set — $40M at Series A in April 2024 — followed by BridGene Biosciences at $28M (Series B, October 2025), the most recent close on record here.
Stage distribution skews early and opaque: two Series A rounds, one Series B, one Series D (Maui Imaging, $14M, July 2025), five rounds with no disclosed series classification, and one debt financing event — Tosk's $100K raise in September 2022, the smallest amount in the dataset. Cantabio Pharmaceuticals and Proxim Diagnostics both closed rounds in 2023 without publishing amounts. Four of the 10 rounds occurred in 2025 alone, suggesting continued deal flow into the South Bay biotech corridor.
Most recent rounds
10 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Sunnyvale biotech companies?
Rubedo Life Sciences leads at $40M (Series A, April 2024), followed by BridGene Biosciences at $28M (Series B, October 2025) and Maui Imaging at $14M (Series D, July 2025). Those three rounds account for the majority of disclosed capital in this 10-company snapshot.
How many companies in this set have not disclosed their round size?
Two — Cantabio Pharmaceuticals and Proxim Diagnostics — closed rounds in 2023 without publishing amounts. All other eight companies disclosed figures ranging from $100K (Tosk, debt financing) to $40M (Rubedo Life Sciences).
Which company represents the most advanced funding stage here?
Maui Imaging's Series D ($14M, July 2025) is the most mature stage in this dataset. BridGene Biosciences at Series B ($28M, October 2025) is the next most advanced, while the majority of companies are Series A or at an undisclosed early stage.
How has funding activity in this segment been distributed across years?
2025 accounts for four of the 10 rounds (BridGene Biosciences, Maui Imaging, Fluxus, PETcoil), 2024 contributed two (MiLaboratories, Rubedo Life Sciences), 2023 had three (Cantabio Pharmaceuticals, QuantumCyte, Proxim Diagnostics), and 2022 produced a single event — Tosk's $100K debt financing.
What round types appear in this Sunnyvale biotech segment?
Five of the 10 rounds carry an unknown series classification, making it the most common label. Series A appears twice (MiLaboratories, Rubedo Life Sciences), with one Series B (BridGene Biosciences), one Series D (Maui Imaging), and one debt financing round (Tosk) completing the breakdown.
Which company closed funding most recently in this dataset?
BridGene Biosciences closed a $28M Series B on October 18, 2025, making it the most recent event. Maui Imaging's $14M Series D in July 2025 is the second most recent.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.